pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Kyprolis
drug · protein
save

carfilzomib

Marketedupdated 6mo ago
by $AMGN AMGEN INC🔗 ChEMBL
Approved
community read0 votes

Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and multiple myeloma and 12 investigational indications.

targets

26S proteasome

all catalysts(0)

nothing on the calendar yet

Trials studying carfilzomib

  • phase1A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myelomarecruitingn=165
  • phase3A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myelomarecruitingn=520
  • phase1A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatmentsrecruitingn=317
  • phase1A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myelomaactive not recruitingn=166
  • phase2Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myelomarecruitingn=70
  • phase2A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myelomarecruitingn=246
  • phase2Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MMactive not recruitingn=44
  • phase3A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)recruitingn=915

Patent cliff

source: FDA Orange Book
first barrier falls
Jan 20, 2027
59 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (24)

  • Aug 27, 2033patentUS 9493582*PED
  • Aug 27, 2033patentUS 9493582*PED
  • Aug 27, 2033patentUS 9493582*PED
  • Feb 27, 2033formulationUS 9493582
  • Feb 27, 2033formulationUS 9493582
  • Feb 27, 2033formulationUS 9493582
  • Apr 21, 2030patentUS RE47954*PED3.4y
  • Apr 21, 2030patentUS RE47954*PED3.4y
  • Apr 21, 2030patentUS RE47954*PED3.4y
  • Oct 21, 2029method-of-use (U-3449)US RE479542.9y
  • Oct 21, 2029method-of-use (U-3449)US RE479542.9y
  • Oct 21, 2029method-of-use (U-3449)US RE479542.9y
  • Jun 7, 2028patentUS 7737112*PED1.5y
  • Jun 7, 2028patentUS 7737112*PED1.5y
  • Jun 7, 2028patentUS 7737112*PED1.5y
  • Dec 7, 2027formulationUS 77371121.0y
  • Dec 7, 2027formulationUS 77371121.0y
  • Dec 7, 2027formulationUS 77371121.0y
  • Jan 20, 2027patentUS 7417042*PED59d
  • Jan 20, 2027patentUS 7417042*PED59d
  • Jan 20, 2027patentUS 7417042*PED59d
  • Jul 20, 2026compositionUS 7417042
  • Jul 20, 2026compositionUS 7417042
  • Jul 20, 2026compositionUS 7417042

FDA exclusivities (6)

  • Nov 22, 2028PEDPediatric (6mo bonus)2.0y
  • Nov 22, 2028PEDPediatric (6mo bonus)2.0y
  • Nov 22, 2028PEDPediatric (6mo bonus)2.0y
  • May 22, 2028M-14Method (3y)1.5y
  • May 22, 2028M-14Method (3y)1.5y
  • May 22, 2028M-14Method (3y)1.5y

News(2)

  • Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
    The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.
    biopharma_dive · 3mo ago
  • Bristol Myers unveils data for one of its next-gen blood cancer drugs
    Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.
    biopharma_dive · 5mo ago
brand
Kyprolis
trade names
Kyprolis
generic
carfilzomib
MOA
26S proteasome inhibitor
indication
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?